PRME Prime Medicine, Inc.
Financings ·
Prime sold 38,000,000 shares at $3.30, below the $3.83 closing price on July 29, 2025. The estimated net proceeds are $120.2 million, and the auditor's 2024 report carries a going-concern paragraph.
We have not published a story on Prime Medicine yet. When there is news, it will appear here.
Prime Medicine is a biotechnology company developing genetic medicines based on Prime Editing, a gene editing approach that makes targeted DNA modifications without double-stranded breaks. Prime Editing uses a Cas9 nickase fused to a reverse transcriptase, guided by a prime editing guide RNA (pegRNA). Its wholly owned in vivo programs target liver diseases and cystic fibrosis (CF), with the CF program supported by the Cystic Fibrosis Foundation. The lead program, PM577, is designed to correct the H1069Q mutation in the ATP7B gene for Wilson Disease and is supported by preclinical data in animal models. PM647 is being advanced for alpha-1 antitrypsin deficiency (AATD). Partnered ex vivo programs with Bristol-Myers Squibb apply Prime Editing to T-cell engineering. Early clinical data from the ex vivo program PM359 for CGD demonstrated restoration of functional protein activity in treated patients. The company describes a modular platform with shared delivery and manufacturing pathways across programs.
| Product or program | What it is | Stage |
|---|---|---|
| PM577 | Prime Editor designed to correct the H1069Q mutation in ATP7B for Wilson Disease | preclinical |
| PM647 | Liver-targeted program for alpha-1 antitrypsin deficiency | being advanced |
| PM359 | Ex vivo Prime Editing program for CGD | early clinical data reported |
| CF program | Prime Editing for cystic fibrosis, delivered by lipid nanoparticles or AAV | progressing |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $4.6 million | $3.0 million |
| Research and development | $160.6 million | $155.3 million |
| Net income (loss) | -$201.1 million | -$195.9 million |
| Cash from operations | -$162.6 million | -$122.9 million |
| Cash and equivalents | $63.0 million | $182.5 million |
| Short-term investments | $114.6 million |
Our latest story on this, dated Jul 30, 2025: "Prime Medicine prices 38,000,000 share offering at $3.30, $125,400,000 gross". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 30, 2025: "Prime Medicine prices 38,000,000 share offering at $3.30, $125,400,000 gross". The story links the filing or release it is based on. Read the story.
Prime Medicine, Inc. trades under the ticker PRME on NASDAQ.
Prime Medicine, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Prime Medicine, Inc. is 1894562. Its filings are on SEC EDGAR.
181,376,856 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Prime Medicine, Inc. under United States.
Our directory classifies Prime Medicine, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Prime Medicine, Inc. is US74168J1016.
aibio.space lists Prime Medicine, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Prime Medicine is a biotechnology company developing genetic medicines based on Prime Editing, a gene editing approach that makes targeted DNA modifications without double-stranded breaks. Prime Editing uses a Cas9 nickase fused to a reverse transcriptase, guided by a prime editing guide RNA (pegRNA).
PM577: Prime Editor designed to correct the H1069Q mutation in ATP7B for Wilson Disease Stage: preclinical.
PM647: Liver-targeted program for alpha-1 antitrypsin deficiency Stage: being advanced.
$4.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio